Tumour Antigen Choice

With the advent of powerful therapeutic options such as antibody therapy, TCR gene transfer, and chimeric antigen receptors, tumour antigen selection is emerging as a critical factor in potentiating immune responses that selectively and safely target tumour tissue. CIIC members are exploring novel tumour associated antigens, both MHC-restricted antigens, and intact cell surface antigens, in the context of both conventional and virus-associated malignancies.